Kyowa acquires Lonza production technology
This article was originally published in Scrip
Executive Summary
Kyowa Hakko and its US antibody technology subsidiary BioWa have licensedLonza's glutamine synthetase (GS) gene expression system for use in the production of antibodies and recombinant proteins under development by the Japanese firm. The worldwide, non-exclusive deal adds to the basic research collaboration signed previously by the two firms to examine combining the GS system with BioWa's Potelligent antibody potency-enhancing technology. Kyowa will merge with Japan's Kirin Pharma in October to form Kyowa Hakko Kirin.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.